bioAffinity Technologies, Inc. (BIAF) Revenue History
Annual and quarterly revenue from 2019 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BIAF Revenue Growth
Revenue Breakdown (FY 2024)
BIAF's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
BIAF Revenue Analysis (2019–2024)
As of May 8, 2026, bioAffinity Technologies, Inc. (BIAF) generated trailing twelve-month (TTM) revenue of $6.8 million, reflecting significant decline in growth of -38.5% year-over-year. The most recent quarter (Q3 2025) recorded $1.4 million in revenue, up 13.9% sequentially.
Looking at the longer-term picture, BIAF's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $9.4 million in 2024, representing a new all-time high.
Revenue diversification analysis shows BIAF's business is primarily driven by Health Care, Patient Service (100%). With over half of revenue concentrated in Health Care, Patient Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LUNG (+8.0% YoY), NVCR (+8.5% YoY), and CDNA (+19.2% YoY), BIAF has underperformed the peer group in terms of revenue growth. Compare BIAF vs LUNG →
BIAF Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BIAFCurrent | $7M | -38.5% | - | -95.6% | |
 LUNG | $90M | +8.0% | +22.6% | -59.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 GKOS | $507M | +36.3% | +17.7% | -17.1% |
BIAF Historical Revenue Data (2019–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $9.4M | +269.7% | $3.4M | 36.1% | $-8,953,000 | -95.6% |
| 2023 | $2.5M | +52617.1% | $792K | 31.3% | $-7,973,000 | -314.9% |
| 2022 | $5K | - | $4K | 90.3% | $-4,011,058 | -83511.5% |
| 2021 | $0 | - | $-4,817 | - | $-2,206,822 | - |
| 2020 | $0 | - | $-22,242 | - | $-2,604,385 | - |
| 2019 | $0 | - | $-40,278 | - | $-3,092,242 | - |
See BIAF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIAF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIAF vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBIAF — Frequently Asked Questions
Quick answers to the most common questions about buying BIAF stock.
Is BIAF's revenue growth accelerating or slowing?
BIAF revenue declined -38.5% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $7M. This reverses the prior growth trend.
What is BIAF's long-term revenue growth rate?
bioAffinity Technologies, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -38.5% is below this long-term average.
How is BIAF's revenue distributed by segment?
BIAF reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2024 are available for download. Segment mix reveals concentration and diversification trends.